Andreas A Hombach
Overview
Explore the profile of Andreas A Hombach including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
1621
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barden M, Elsenbroich P, Haas V, Ertelt M, Pervan P, Velas L, et al.
J Immunother Cancer
. 2024 Dec;
12(12.
PMID: 39622582
Background: The success of chimeric antigen receptor (CAR) T cell therapy for hematological malignancies has not yet translated into long-term elimination of solid tumors indicating the need for adequately tuning...
2.
Barden M, Holzinger A, Velas L, Mezosi-Csaplar M, Szoor A, Vereb G, et al.
Front Immunol
. 2023 Feb;
14:1110482.
PMID: 36817444
In engineered T cells the CAR is co-expressed along with the physiological TCR/CD3 complex, both utilizing the same downstream signaling machinery for T cell activation. It is unresolved whether CAR-mediated...
3.
Hombach A, Ambrose C, Lobb R, Rennert P, Abken H
Cells
. 2023 Jan;
12(2).
PMID: 36672182
The efficacy of CD19-specific CAR T cells in the treatment of leukemia/lymphoma relies, at least in part, on the unique properties of the particular CAR and the presence of healthy...
4.
Hombach A, Geumann U, Gunther C, Hermann F, Abken H
Cells
. 2020 Apr;
9(4).
PMID: 32260097
Chimeric antigen receptor (CAR) redirected T cells are efficacious in the treatment of leukemia/lymphoma, however, showed less capacities in eliminating solid tumors which is thought to be partly due to...
5.
Hombach A, Rappl G, Abken H
Mol Ther
. 2019 Jul;
27(10):1825-1835.
PMID: 31331813
Chimeric antigen receptor (CAR)-engineered T cells are efficacious in controlling advanced leukemia and lymphoma, however, they fail in the treatment of solid cancer, which is thought to be due to...
6.
Golumba-Nagy V, Kuehle J, Hombach A, Abken H
Mol Ther
. 2018 Jul;
26(9):2218-2230.
PMID: 30055872
Adoptive cell therapy with chimeric antigen receptor (CAR)-redirected T cells induced spectacular regressions of leukemia and lymphoma, however, failed so far in the treatment of solid tumors. A cause is...
7.
Martyniszyn A, Krahl A, Andre M, Hombach A, Abken H
Hum Gene Ther
. 2017 Dec;
28(12):1147-1157.
PMID: 29207878
The treatment of leukemia/lymphoma by chimeric antigen receptor (CAR) redirected T cells with specificity for CD19 induced complete remissions in the majority of patients, with a realistic hope for cure....
8.
Hombach A, Abken H
Cancers (Basel)
. 2017 Aug;
9(9).
PMID: 28850063
Evidences are accumulating that CD4⁺ T cells can physiologically mediate antigen specific target cell lysis. By circumventing major histocompatibility complex (MHC)-restrictions through an engineered chimeric antigen receptor (CAR), CD4⁺ T...
9.
Hombach A, Abken H
Expert Rev Clin Immunol
. 2016 Aug;
13(2):151-155.
PMID: 27546707
Adoptive therapy with chimeric antigen receptor (CAR) T cells redirected towards CD19 produces remissions of B cell malignancies, however, it also eradicates healthy B cells sharing the target antigen. Such...
10.
Faitschuk E, Hombach A, Frenzel L, Wendtner C, Abken H
Blood
. 2016 Aug;
128(13):1711-22.
PMID: 27535994
Adoptive cell therapy of chronic lymphocytic leukemia (CLL) with chimeric antigen receptor (CAR)-modified T cells targeting CD19 induced lasting remission of this refractory disease in a number of patients. However,...